Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN7A | Q01118 | 7/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759359 | 0.89 | SCN7A (0.49) | SCN7ASCN5ASCN9ASCN4ASCN1A | |
| SCHEMBL16771204 | 0.87 | SCN7A (0.49) | SCN7ASCN5ASCN9ASCN4A | |
| SCHEMBL16771163 | 0.86 | SCN9A (0.61) | SCN7ASCN5ASCN9ASCN4A | |
| Hydrochloric Acid SCHEMBL16759287 | 0.86 | SCN7A (0.49) | SCN7ASCN5ASCN9ASCN4A | |
| SCHEMBL17062049 | 0.84 | SCN7A (0.71) | SCN7ASCN5ASCN9ASCN4ASCN1A | |
| SCHEMBL20868348 | 0.82 | SCN9A (0.46) | SCN7ASCN5ASCN9ASCN4A | |
| SCHEMBL17061849 | 0.81 | SCN9A (0.71) | SCN7ASCN5ASCN9ASCN4A | |
| SCHEMBL18243704 | 0.80 | SCN7A (0.57) | SCN7ASCN5ASCN9ASCN4A | |
| SCHEMBL21825438 | 0.80 | SCN9A (0.43) | SCN7ASCN5ASCN9ASCN4ASCN1A | |
| Trifluoroacetic Acid SCHEMBL16759202 | 0.80 | SCN7A (0.65) | SCN7ASCN5ASCN9ASCN4ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815197-B2 | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-10-27 | — | — | US | disclosed |
| US-20190023654-A1 | N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815197-B2 | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors | SCN11A, SCN8A, NHERF1 | SCN7A 12/4885SCN5A 9/4885SCN9A 73/4885 |
| US-20190023654-A1 | N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | SLC5A11, SLC6A11, SLC5A1 | SCN7A 82/4885SCN5A 199/4885SCN9A 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.